<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[license agreement and schering-plough corp. Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/license+agreement+and+schering-plough+corp..html?i=11]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to license agreement and schering-plough corp.]]></description>
	<s:counts start="0" returned="4" found="4" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Santarus Achieves $2.5 Million Regulatory Milestone under OTC License Agreement with Schering-Plough]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_27/ai_n25454690]]></link>
		<description><![CDATA[SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has achieved a $2.5 million regulatory milestone under its over-the-counter OTC license agreement with Schering-Plough Healthcare Products, Inc. Santarus expects to receive the $2.5 million payment within the next two weeks. Schering-Plough is seeking U.S. Food...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 27 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Santarus Announces Achievement of $5 Million Milestone Under OTC License Agreement with Schering-Plough]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_20/ai_n27316837]]></link>
		<description><![CDATA[SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that a $5 million milestone relating to progress on clinical product development strategy has been achieved under its over-the-counter OTC license agreement with Schering-Plough HealthCare Products, Inc. for proton pump inhibitor PPI products using Santarus' patented PPI technology.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 20 Jul 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Santarus Announces Effective Date of OTC License Agreement with Schering-Plough]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_21/ai_n27061518]]></link>
		<description><![CDATA[SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that its license agreement with Schering-Plough HealthCare Products, Inc. for the development, manufacturing and commercialization of ZEGERID([R]) brand products for the over-the-counter OTC market is now effective, following the expiration...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 21 Nov 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Teva and Schering-Plough Enter into License Agreement Covering Schering-Plough's Ribavirin Patents]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2003_March_26/ai_99216467]]></link>
		<description><![CDATA[Business Editors/Health/Medical Writers]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 26 Mar 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
</channel>
</rss>
